Severity, Criticality, and Fatality of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Beta Variant

doi:10.1093/cid/ciab909

. 2022 Aug 24;75(1):e1188-e1191.

doi: 10.1093/cid/ciab909.

Severity, Criticality, and Fatality of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Beta Variant

Laith J Abu-Raddad^{1

2

3

4}, Hiam Chemaitelly^{1

2}, Houssein H Ayoub⁵, Hadi M Yassine^{6

7}, Fatiha M Benslimane^{6

7}, Hebah A Al Khatib^{6

7}, Patrick Tang⁸, Mohammad R Hasan⁸, Peter Coyle^{6

9

10}, Sawsan AlMukdad^{1

2}, Zaina Al Kanaani⁹, Einas Al Kuwari⁹, Andrew Jeremijenko⁹, Anvar Hassan Kaleeckal⁹, Ali Nizar Latif⁹, Riyazuddin Mohammad Shaik⁹, Hanan F Abdul Rahim⁴, Gheyath K Nasrallah^{6

7}, Mohamed Ghaith Al Kuwari¹¹, Adeel A Butt^{3

9}, Hamad Eid Al Romaihi¹², Mohamed H Al-Thani¹², Abdullatif Al Khal⁹, Roberto Bertollini¹²

Affiliations

¹ Infectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University, Qatar Foundation-Education City, Doha, Qatar.
² World Health Organization Collaborating Centre for Disease Epidemiology Analytics on HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis, Weill Cornell Medicine-Qatar, Cornell University, Qatar Foundation-Education City, Doha, Qatar.
³ Department of Population Health Sciences, Weill Cornell Medicine, Cornell University, New York, New York, USA.
⁴ Department of Public Health, College of Health Sciences, Member of QU Health, Qatar University, Doha, Qatar.
⁵ Mathematics Program, Department of Mathematics, Statistics, and Physics, College of Arts and Sciences, Qatar University, Doha, Qatar.
⁶ Biomedical Research Center, Member of QU Health, Qatar University, Doha, Qatar.
⁷ Department of Biomedical Science, College of Health Sciences, Member of QU Health, Qatar University, Doha, Qatar.
⁸ Department of Pathology, Sidra Medicine, Doha, Qatar.
⁹ Hamad Medical Corporation, Doha, Qatar.
¹⁰ Wellcome-Wolfson Institute for Experimental Medicine, Queens University, Belfast, United Kingdom.
¹¹ Primary Health Care Corporation, Doha, Qatarand.
¹² Ministry of Public Health, Doha, Qatar.

PMID: 34657152
PMCID: PMC9402694
DOI: 10.1093/cid/ciab909

Severity, Criticality, and Fatality of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Beta Variant

Laith J Abu-Raddad et al. Clin Infect Dis. 2022.

. 2022 Aug 24;75(1):e1188-e1191.

doi: 10.1093/cid/ciab909.

Authors

Affiliations

¹ Infectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University, Qatar Foundation-Education City, Doha, Qatar.
² World Health Organization Collaborating Centre for Disease Epidemiology Analytics on HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis, Weill Cornell Medicine-Qatar, Cornell University, Qatar Foundation-Education City, Doha, Qatar.
³ Department of Population Health Sciences, Weill Cornell Medicine, Cornell University, New York, New York, USA.
⁴ Department of Public Health, College of Health Sciences, Member of QU Health, Qatar University, Doha, Qatar.
⁵ Mathematics Program, Department of Mathematics, Statistics, and Physics, College of Arts and Sciences, Qatar University, Doha, Qatar.
⁶ Biomedical Research Center, Member of QU Health, Qatar University, Doha, Qatar.
⁷ Department of Biomedical Science, College of Health Sciences, Member of QU Health, Qatar University, Doha, Qatar.
⁸ Department of Pathology, Sidra Medicine, Doha, Qatar.
⁹ Hamad Medical Corporation, Doha, Qatar.
¹⁰ Wellcome-Wolfson Institute for Experimental Medicine, Queens University, Belfast, United Kingdom.
¹¹ Primary Health Care Corporation, Doha, Qatarand.
¹² Ministry of Public Health, Doha, Qatar.

PMID: 34657152
PMCID: PMC9402694
DOI: 10.1093/cid/ciab909

Abstract

Beta (B.1.351)-variant coronavirus disease 2019 (COVID-19) disease was investigated in Qatar. Compared with the Alpha (B.1.1.7) variant, odds (95% confidence interval) of progressing to severe disease, critical disease, and COVID-19-related death were 1.24-fold (1.11-1.39), 1.49-fold (1.13-1.97), and 1.57-fold (1.03-2.43) higher, respectively, for the Beta variant.

Keywords: SARS-CoV-2; epidemiology; infection; severe disease; variant.

PubMed Disclaimer

Figures

**Figure 1.**
Number of (A) daily new COVID-19 acute-care hospital admissions, (B) daily new COVID-19 ICU hospital admissions, and (C) COVID-19–related deaths in Qatar. Abbreviations: COVID-19, coronavirus disease 2019; ICU, intensive care unit.

See this image and copyright information in PMC

Cited by

Association between Mutations in Papain-like Protease (PLpro) of SARS-CoV-2 with COVID-19 Clinical Outcomes.
Tan J, Wu Z, Hu P, Gan L, Wang Y, Zhang D. Tan J, et al. Pathogens. 2022 Sep 3;11(9):1008. doi: 10.3390/pathogens11091008. Pathogens. 2022. PMID: 36145442 Free PMC article.
One Pandemic, Two Solutions: Comparing the U.S.-China Response and Health Priorities to COVID-19 from the Perspective of "Two Types of Control".
Lyu S, Qian C, McIntyre A, Lee CH. Lyu S, et al. Healthcare (Basel). 2023 Jun 26;11(13):1848. doi: 10.3390/healthcare11131848. Healthcare (Basel). 2023. PMID: 37444682 Free PMC article.
COVID-19 pandemic dynamics in South Africa and epidemiological characteristics of three variants of concern (Beta, Delta, and Omicron).
Yang W, Shaman JL. Yang W, et al. Elife. 2022 Aug 9;11:e78933. doi: 10.7554/eLife.78933. Elife. 2022. PMID: 35943138 Free PMC article.
Characterisation of Omicron Variant during COVID-19 Pandemic and the Impact of Vaccination, Transmission Rate, Mortality, and Reinfection in South Africa, Germany, and Brazil.
Ribeiro Xavier C, Sachetto Oliveira R, da Fonseca Vieira V, Lobosco M, Weber Dos Santos R. Ribeiro Xavier C, et al. BioTech (Basel). 2022 Apr 26;11(2):12. doi: 10.3390/biotech11020012. BioTech (Basel). 2022. PMID: 35822785 Free PMC article.
Excess mortality associated with the COVID-19 pandemic during the 2020 and 2021 waves in Antananarivo, Madagascar.
Rabarison JH, Rakotondramanga JM, Ratovoson R, Masquelier B, Rasoanomenjanahary AM, Dreyfus A, Garchitorena A, Rasambainarivo F, Razanajatovo NH, Andriamandimby SF, Metcalf CJ, Lacoste V, Heraud JM, Dussart P. Rabarison JH, et al. BMJ Glob Health. 2023 Jul;8(7):e011801. doi: 10.1136/bmjgh-2023-011801. BMJ Glob Health. 2023. PMID: 37495370 Free PMC article.

See all "Cited by" articles

References

1. World Health Organization. Tracking SARS-CoV-2 variants. 2021. Available at: https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/. Accessed 5 June 2021.
1. Abu-Raddad LJ, Chemaitelly H, Butt AA; National Study Group for Covid-19 Vaccination. . Effectiveness of the BNT162b2 Covid-19 vaccine against the B.1.1.7 and B.1.351 variants. N Engl J Med 2021; 385:187–9. - PMC - PubMed
1. Chemaitelly H, Yassine HM, Benslimane FM, et al. . mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar. Nat Med 2021; 27:1614–21. - PubMed
1. National Project of Surveillance for Variants of Concern and Viral Genome Sequencing. Qatar viral genome sequencing data. Data on randomly collected samples. Available at: https://www.gisaid.org/phylodynamics/global/nextstrain/. Accessed 11 October 2021.
1. Benslimane FM, Al Khatib HA, Al-Jamal O, et al. . One year of SARS-CoV-2: genomic characterization of COVID-19 outbreak in Qatar. medRxiv [Preprint]. May 20, 2021. Available at: https://www.medrxiv.org/content/10.1101/2021.05.19.21257433v2. Accessed 11 October 2021. - DOI - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions

Supplementary concepts

Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal

[1] World Health Organization. Tracking SARS-CoV-2 variants. 2021. Available at: https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/. Accessed 5 June 2021.

[2] World Health Organization. Tracking SARS-CoV-2 variants. 2021. Available at: https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/. Accessed 5 June 2021.

[3] Abu-Raddad LJ, Chemaitelly H, Butt AA; National Study Group for Covid-19 Vaccination. . Effectiveness of the BNT162b2 Covid-19 vaccine against the B.1.1.7 and B.1.351 variants. N Engl J Med 2021; 385:187–9. - PMC - PubMed

[4] Abu-Raddad LJ, Chemaitelly H, Butt AA; National Study Group for Covid-19 Vaccination. . Effectiveness of the BNT162b2 Covid-19 vaccine against the B.1.1.7 and B.1.351 variants. N Engl J Med 2021; 385:187–9. - PMC - PubMed

[5] Chemaitelly H, Yassine HM, Benslimane FM, et al. . mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar. Nat Med 2021; 27:1614–21. - PubMed

[6] Chemaitelly H, Yassine HM, Benslimane FM, et al. . mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar. Nat Med 2021; 27:1614–21. - PubMed

[7] National Project of Surveillance for Variants of Concern and Viral Genome Sequencing. Qatar viral genome sequencing data. Data on randomly collected samples. Available at: https://www.gisaid.org/phylodynamics/global/nextstrain/. Accessed 11 October 2021.

[8] National Project of Surveillance for Variants of Concern and Viral Genome Sequencing. Qatar viral genome sequencing data. Data on randomly collected samples. Available at: https://www.gisaid.org/phylodynamics/global/nextstrain/. Accessed 11 October 2021.

[9] Benslimane FM, Al Khatib HA, Al-Jamal O, et al. . One year of SARS-CoV-2: genomic characterization of COVID-19 outbreak in Qatar. medRxiv [Preprint]. May 20, 2021. Available at: https://www.medrxiv.org/content/10.1101/2021.05.19.21257433v2. Accessed 11 October 2021. - DOI - PMC - PubMed

[10] Benslimane FM, Al Khatib HA, Al-Jamal O, et al. . One year of SARS-CoV-2: genomic characterization of COVID-19 outbreak in Qatar. medRxiv [Preprint]. May 20, 2021. Available at: https://www.medrxiv.org/content/10.1101/2021.05.19.21257433v2. Accessed 11 October 2021. - DOI - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Severity, Criticality, and Fatality of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Beta Variant

Affiliations

Severity, Criticality, and Fatality of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Beta Variant

Authors

Affiliations

Abstract

Figures

Similar articles

Cited by

References

Publication types

MeSH terms

Supplementary concepts

LinkOut - more resources

Full Text Sources

Medical

Miscellaneous

Abstract

Figures

Similar articles

Cited by

References

Publication types

MeSH terms

Supplementary concepts

Related information

LinkOut - more resources

Full Text Sources

Medical

Miscellaneous